Third Arc Bio

Third Arc Bio is a private, preclinical-stage biotech pioneering a new class of multifunctional antibody therapeutics, which it terms the 'Third Arc' of biologics. The company's platform is designed to engineer optimized biologics that engage multiple targets and cell types by leveraging immune synapse biology, aiming to overcome limitations in treating solid tumors and autoimmune diseases. Led by a seasoned team with a collective history of over 35 drug approvals, the company is backed by venture capital and is actively building its pipeline. Its recent Series A extension provides capital to grow its oncology and I&I portfolios.

Platform for engineering multifunctional antibodies designed to optimize immune synapse biology by engaging multiple targets and cell types to treat complex diseases.

Third Arc Bio competes in the rapidly advancing field of multispecific and engineered antibody therapeutics, facing competition from large pharma (e.g., Roche, Genentech, Amgen) and numerous biotechs (e.g., Immunocore, Affimed, IGM Biosciences). Differentiation will depend on the unique biology of its immune synapse-focused approach and its ability to demonstrate clinical superiority.